ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

ANIP 11.04.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-13
Name of Upcoming Event:The Guggenheim Inaugural Healthcare Innovation Conference
Date of Upcoming Event:2024-11-20
Name of Upcoming Event:The Jefferies London Healthcare Conference
Full Press ReleaseSEC FilingsOur ANIP Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
  • 01.02.2025 - ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

Recent Filings

  • 01.21.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows:

• The Guggenheim Inaugural Healthcare Innovation Conference

Wednesday, November 13, 2024, at 10:00am ET

• The Jefferies London Healthcare Conference

Wednesday, November 20, 2024, at 2:30pm GMT/9:30am ET

The live and archived webcasts will be accessible from the Company’s website atwww.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visitwww.anipharmaceuticals.com.

Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E:lwilson@insitecony.com

Source: ANI Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com